Nicox S.A. (LON: 0RCQ)

Market Cap	17.57M
Revenue (ttm)	3.07M
Net Income (ttm)	-14.91M
Shares Out	n/a
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	738
Average Volume	5,008
Open	0.307
Previous Close	0.299
Day's Range	0.299 - 0.307
52-Week Range	0.137 - 0.407
Beta	0.89
RSI	54.40
Earnings Date	Jan 23, 2025

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2022, Nicox's revenue was 3.27 million, a decrease of -54.78% compared to the previous year's 7.23 million. Losses were -27.76 million, -36.57% less than in 2021.

Financial numbers in EUR